Eupraxia Pharmaceuticals Inc. (EPRX) Financial Analysis & Valuation | Quarter Chart
Eupraxia Pharmaceuticals Inc. (EPRX)
EPRXPrice: $7.08
Fair Value: 🔒
🔒score
Description
Shares
| Market Cap | $237.04M | Exchange | NASDAQ |
| Sector | — | Industry | — |
| Country | — | CEO | James A. Helliwell |
| IPO Date | 2024-04-05 | CAGR | — |
| Employees | 33 | Website | — |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
EPRX chart loading...
Fundamentals
Technicals
| Enterprise Value | $427.27M | P/E Ratio | -6.87 |
| Forward P/E | -11.24 | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | 4.52 |
| P/CF Ratio | -15.68 | P/FCF Ratio | -10.63 |
| EPS | $-1.03 | EPS Growth 1Y | 78.95% |
| EPS Growth 3Y | 13.33% | EPS Growth 5Y | 300.59% |
| Revenue Growth 1Y | — | Gross Margin | — |
| Operating Margin | — | Profit Margin | — |
| ROE | -0.66% | ROA | -0.4% |
| ROCE | -0.43% | Current Ratio | 15.12 |
| Quick Ratio | 15.12 | Cash Ratio | 14.31 |
| Debt/Equity | 0 | Interest Coverage | — |
| Altman Z Score | 23.64 | Piotroski Score | 2 |